April 10, 2019
Medwatcher Japan, a citizen’s drug damage watchdog, is leaning on the health ministry and Shionogi to suspend sales of the company’s anti-flu agent Xofluza (baloxavir marboxil) as growing concerns over a high rate of drug resistance overshadow its strong uptake...read more